Suppr超能文献

在 4-苯胺基取代的吡咯并[2,3-d]嘧啶中，2-氨基基团对受体酪氨酸激酶抑制和抗血管生成活性的贡献。

The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines.

机构信息

Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, USA.

出版信息

Bioorg Med Chem Lett. 2010 May 15;20(10):3177-81. doi: 10.1016/j.bmcl.2010.03.064. Epub 2010 Mar 24.

DOI:10.1016/j.bmcl.2010.03.064
PMID:20403693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2866134/
Abstract

Comparison between a series of pyrrolo[2,3-d]pyrimidines with and without the 2-amino group is presented in order to determine the validity of our hypothesis that inclusion of this group improves potency against receptor tyrosine kinases (RTK). The 2-amino analogs were better against epidermal growth factor receptor (EGFR) and platelet derived growth factor-beta (PDGFR-beta) in whole cell inhibition assays and in the A431 cytotoxicity assay compared to the 2-desamino analogs. However, the 2-desamino analogs were more potent inhibitors against vascular endothelial growth factor-2 (VEGFR-2) than the corresponding 2-amino compounds. In addition, none of the 2-desamino compounds exhibited better anti-angiogenic activity in the chorioallantoic membrane (CAM) assay as compared to the standard and were only micromolar inhibitors. This study validates our original hypothesis that the inclusion of a 2-amino group in pyrrolo[2,3-d]pyrimidines improves multiple RTK inhibition and antiangiogenic activity.

摘要

为了确定我们的假设（即包含 2-氨基基团可以提高对受体酪氨酸激酶（RTK）的效力）的有效性，我们对一系列具有和不具有 2-氨基基团的吡咯并[2,3-d]嘧啶进行了比较。在全细胞抑制测定和 A431 细胞毒性测定中，2-氨基类似物比 2-去氨基类似物对表皮生长因子受体（EGFR）和血小板衍生生长因子-β（PDGFR-β）的抑制作用更好。然而，2-去氨基类似物对血管内皮生长因子-2（VEGFR-2）的抑制作用比相应的 2-氨基化合物更强。此外，与标准品相比，没有任何 2-去氨基化合物在鸡胚尿囊膜（CAM）测定中表现出更好的抗血管生成活性，并且仅为微摩尔抑制剂。这项研究验证了我们最初的假设，即在吡咯并[2,3-d]嘧啶中包含 2-氨基基团可以提高多种 RTK 抑制和抗血管生成活性。

相似文献

1
The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines.
Bioorg Med Chem Lett. 2010 May 15;20(10):3177-81. doi: 10.1016/j.bmcl.2010.03.064. Epub 2010 Mar 24.
2
Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
Bioorg Med Chem. 2008 May 15;16(10):5514-28. doi: 10.1016/j.bmc.2008.04.019. Epub 2008 Apr 14.
3
Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.
Bioorg Med Chem. 2010 Jul 15;18(14):5261-73. doi: 10.1016/j.bmc.2010.05.049. Epub 2010 May 25.
4
Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases.
Bioorg Med Chem. 2003 Nov 17;11(23):5155-70. doi: 10.1016/j.bmc.2003.08.034.
5
Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Bioorg Med Chem. 2005 Sep 15;13(18):5475-91. doi: 10.1016/j.bmc.2005.04.087.
6
N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors.
Bioorg Med Chem. 2012 Jan 15;20(2):910-4. doi: 10.1016/j.bmc.2011.11.058. Epub 2011 Dec 8.
7
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Bioorg Med Chem. 2017 Jan 15;25(2):545-556. doi: 10.1016/j.bmc.2016.11.026. Epub 2016 Nov 15.
8
N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents.
Bioorg Med Chem. 2013 Mar 1;21(5):1312-23. doi: 10.1016/j.bmc.2012.12.045. Epub 2013 Jan 10.
9
Design, synthesis and preclinical evaluation of 5-methyl-N-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential.
Bioorg Med Chem Lett. 2018 Oct 1;28(18):3085-3093. doi: 10.1016/j.bmcl.2018.07.039. Epub 2018 Jul 27.
10
The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.
Bioorg Med Chem. 2015 May 15;23(10):2408-23. doi: 10.1016/j.bmc.2015.03.061. Epub 2015 Mar 30.

引用本文的文献

1
Pyrrolo[2,3-D]Pyrimidines as EGFR and VEGFR Kinase Inhibitors: A Comprehensive SAR Review.
Curr Med Chem. 2024;31(36):5918-5936. doi: 10.2174/0929867331666230815115111.
2
A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure-Activity Relationship.
Front Chem. 2022 Jun 13;10:861288. doi: 10.3389/fchem.2022.861288. eCollection 2022.
3
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Bioorg Med Chem. 2017 Jan 15;25(2):545-556. doi: 10.1016/j.bmc.2016.11.026. Epub 2016 Nov 15.
4
N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents.
Bioorg Med Chem. 2013 Mar 1;21(5):1312-23. doi: 10.1016/j.bmc.2012.12.045. Epub 2013 Jan 10.
5
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Bioorg Med Chem. 2012 Jul 15;20(14):4217-25. doi: 10.1016/j.bmc.2012.05.068. Epub 2012 Jun 6.

本文引用的文献

1
Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
Bioorg Med Chem. 2008 May 15;16(10):5514-28. doi: 10.1016/j.bmc.2008.04.019. Epub 2008 Apr 14.
2
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Mol Cancer Res. 2007 Mar;5(3):203-20. doi: 10.1158/1541-7786.MCR-06-0404.
3
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Semin Oncol. 2006 Aug;33(4):407-20. doi: 10.1053/j.seminoncol.2006.04.005.
4
Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?
Eur J Cancer. 2006 Jul;42(10):1351-6. doi: 10.1016/j.ejca.2006.02.013. Epub 2006 Jun 5.
5
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Mol Cancer Ther. 2006 May;5(5):1280-9. doi: 10.1158/1535-7163.MCT-03-0156.
6
Angiogenesis.
Annu Rev Med. 2006;57:1-18. doi: 10.1146/annurev.med.57.121304.131306.
7
Gefitinib--a novel targeted approach to treating cancer.
Nat Rev Cancer. 2004 Dec;4(12):956-65. doi: 10.1038/nrc1506.
8
Epidermal growth factor receptor in tumor angiogenesis.
Hematol Oncol Clin North Am. 2004 Oct;18(5):1007-21, viii. doi: 10.1016/j.hoc.2004.06.002.
9
Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases.
Bioorg Med Chem. 2003 Nov 17;11(23):5155-70. doi: 10.1016/j.bmc.2003.08.034.
10
The biology of VEGF and its receptors.
Nat Med. 2003 Jun;9(6):669-76. doi: 10.1038/nm0603-669.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验